Jonathan Rothberg - Hyperfine Founder Chairman
| HYPR Stock | USD 1.19 0.05 4.03% |
Insider
Jonathan Rothberg is Founder Chairman of Hyperfine
| Age | 62 |
| Phone | 866 796 6767 |
| Web | https://hyperfine.io |
Jonathan Rothberg Latest Insider Activity
Tracking and analyzing the buying and selling activities of Jonathan Rothberg against Hyperfine stock is an integral part of due diligence when investing in Hyperfine. Jonathan Rothberg insider activity provides valuable insight into whether Hyperfine is net buyers or sellers over its current business cycle. Note, Hyperfine insiders must abide by specific rules, including filing SEC forms every time they buy or sell Hyperfine'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Jonathan Rothberg over two weeks ago Disposition of 335834 shares by Jonathan Rothberg of Butterfly Network at 4.1822 subject to Rule 16b-3 | ||
Jonathan Rothberg over a month ago Disposition of 2673 shares by Jonathan Rothberg of Butterfly Network at 4.0 subject to Rule 16b-3 | ||
Jonathan Rothberg over a month ago Disposition of 123354 shares by Jonathan Rothberg of Butterfly Network at 3.0816 subject to Rule 16b-3 | ||
Jonathan Rothberg over a month ago Acquisition by Jonathan Rothberg of 113281 shares of Quantum Si at 1.86 subject to Rule 16b-3 |
Hyperfine Management Efficiency
The company has return on total asset (ROA) of (0.4529) % which means that it has lost $0.4529 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9403) %, meaning that it created substantial loss on money invested by shareholders. Hyperfine's management efficiency ratios could be used to measure how well Hyperfine manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Lisa MD | Vivani Medical | 62 | |
| Brigid Makes | Vivani Medical | 68 | |
| LLM LLM | Quince Therapeutics | 54 | |
| Erin Liberto | Avita Medical | 49 | |
| Michael MBA | Avita Medical | 61 | |
| Andrew Quick | Avita Medical | 53 | |
| Kathy McGee | Avita Medical | 58 | |
| Malinda Longphre | Connect Biopharma Holdings | N/A | |
| Steven Chan | Connect Biopharma Holdings | 52 | |
| William MD | Quipt Home Medical | 66 | |
| Roei Samuri | InspireMD | N/A | |
| Derrick Sung | Pulmonx Corp | 53 | |
| Truc MBA | Vivani Medical | 73 | |
| Geoffrey Rose | Pulmonx Corp | 52 | |
| Lei Sun | Connect Biopharma Holdings | 62 | |
| Leslie Becker | Quipt Home Medical | N/A | |
| Adam Mendelsohn | Vivani Medical | 43 | |
| Raul Collazo | Connect Biopharma Holdings | 58 | |
| Hardik Mehta | Quipt Home Medical | 44 | |
| Stewart Low | Quince Therapeutics | N/A | |
| Leslie Holsinger | Quince Therapeutics | 59 | |
Management Performance
| Return On Equity | -0.94 | |||
| Return On Asset | -0.45 |
Hyperfine Leadership Team
Elected by the shareholders, the Hyperfine's board of directors comprises two types of representatives: Hyperfine inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Hyperfine. The board's role is to monitor Hyperfine's management team and ensure that shareholders' interests are well served. Hyperfine's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Hyperfine's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Scott White, Chief Officer | ||
| Neela Paykel, Gen Officer | ||
| Rafael Donnay, Senior Economics | ||
| Rafael OHalloran, Vice Technology | ||
| Alok Gupta, Chief Officer | ||
| Thomas Teisseyre, Chief Officer | ||
| Dave Castiglioni, Chief Officer | ||
| Maria Sainz, President CEO | ||
| Brett Hale, CFO, Officer | ||
| Edmond MD, Chief Officer | ||
| Rob Fasciano, Chief Officer | ||
| Mark Hughes, VP Operations | ||
| Jonathan Rothberg, Founder Chairman | ||
| Khan MD, Chief Officer | ||
| Maria DegoisSainz, President CEO | ||
| Kyla JD, Chief Officer | ||
| MD FACR, Senior Partnerships | ||
| Tom Teisseyre, Chief Officer |
Hyperfine Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Hyperfine a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.94 | |||
| Return On Asset | -0.45 | |||
| Operating Margin | (2.60) % | |||
| Current Valuation | 99.11 M | |||
| Shares Outstanding | 82.11 M | |||
| Shares Owned By Insiders | 4.95 % | |||
| Shares Owned By Institutions | 10.95 % | |||
| Number Of Shares Shorted | 854 K | |||
| Price To Book | 4.48 X | |||
| Price To Sales | 11.38 X |
Pair Trading with Hyperfine
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Hyperfine position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Hyperfine will appreciate offsetting losses from the drop in the long position's value.Moving against Hyperfine Stock
| 0.57 | BAC | Bank of America | PairCorr |
| 0.47 | VZ | Verizon Communications Earnings Call This Week | PairCorr |
| 0.46 | CSCO | Cisco Systems Aggressive Push | PairCorr |
The ability to find closely correlated positions to Hyperfine could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Hyperfine when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Hyperfine - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Hyperfine to buy it.
The correlation of Hyperfine is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Hyperfine moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Hyperfine moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Hyperfine can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Hyperfine Stock Analysis
When running Hyperfine's price analysis, check to measure Hyperfine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hyperfine is operating at the current time. Most of Hyperfine's value examination focuses on studying past and present price action to predict the probability of Hyperfine's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hyperfine's price. Additionally, you may evaluate how the addition of Hyperfine to your portfolios can decrease your overall portfolio volatility.